Skip to main content

Table 3 Summary of the Strengths and Limitations of Ovarian Cancer Immunotherapy

From: Ovarian cancer immunotherapy: opportunities, progresses and challenges

Strategies

Pros

Cons

Antibody-based vaccine

Tumor antigen specific. Easy to produce.

Weak immunogenicity. Not for all individuals.

Peptide vaccine

Safe, stable, and easy to produce and modify.

Poor immunogenicity. HLA restriction.

Cytokine vaccine

Easy to manufacture and administer.

Non-specific immunomodulating only.

Tumor cell vaccine

Convenience, contained tumor antigen pool.

Potential safety concern. Difficult to produce. Difficult to standardize.

Dendritic cell vaccine

Powerful professional antigen presenting cells. May prime both T cells and antibody response.

Difficult to manufacture and standardize.

HSP vaccine

May contain multiple antigens.

Difficult to manufacture and standardize.

Immunomodulation with Treg blockage

Promising strategy

No data on ovarian cancer yet

Difficult to completely eliminate Treg.